Published in Hepatology on January 01, 2008
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotechnol (2010) 3.44
Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med (2010) 3.09
Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc Natl Acad Sci U S A (2013) 2.99
Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology (2008) 2.91
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med (2013) 2.63
NS3 helicase domains involved in infectious intracellular hepatitis C virus particle assembly. J Virol (2008) 2.62
Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology (2012) 2.14
Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90. PLoS Pathog (2014) 2.13
Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J Virol (2010) 2.12
Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology (2010) 1.92
Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology (2009) 1.89
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol (2009) 1.87
Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation. Nat Med (2014) 1.86
Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc Natl Acad Sci U S A (2008) 1.83
Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology (2009) 1.72
The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol (2013) 1.69
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2010) 1.67
RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog (2009) 1.65
Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. Hepatology (2011) 1.54
Immune responses to HCV and other hepatitis viruses. Immunity (2014) 1.52
Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol (2008) 1.48
Identification of transferrin receptor 1 as a hepatitis C virus entry factor. Proc Natl Acad Sci U S A (2013) 1.43
Hepatitis C virus: assembly and release of virus particles. J Biol Chem (2010) 1.42
Effect of cell polarization on hepatitis C virus entry. J Virol (2007) 1.41
Molecular determinants and dynamics of hepatitis C virus secretion. PLoS Pathog (2012) 1.41
Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines (2011) 1.37
The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol (2009) 1.36
Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology (2010) 1.35
Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br J Pharmacol (2013) 1.33
A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology (2011) 1.28
Current progress in development of hepatitis C virus vaccines. Nat Med (2013) 1.28
Unique ties between hepatitis C virus replication and intracellular lipids. Trends Endocrinol Metab (2011) 1.27
Cell-to-Cell Spread of Retroviruses. Viruses (2010) 1.27
Hepatitis C virus infection causes cell cycle arrest at the level of initiation of mitosis. J Virol (2011) 1.24
Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver. Gastroenterology (2013) 1.23
Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med (2014) 1.22
Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. J Virol (2013) 1.20
Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J Virol (2010) 1.18
Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. Gastroenterology (2009) 1.17
Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants. PLoS Pathog (2011) 1.16
Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines (2009) 1.16
A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog (2010) 1.16
Virion assembly and release. Curr Top Microbiol Immunol (2013) 1.15
Griffithsin has antiviral activity against hepatitis C virus. Antimicrob Agents Chemother (2011) 1.14
Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J Virol (2009) 1.13
Integrative functional genomics of hepatitis C virus infection identifies host dependencies in complete viral replication cycle. PLoS Pathog (2014) 1.11
Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection. Proc Natl Acad Sci U S A (2009) 1.11
Production of infectious hepatitis C virus by using RNA polymerase I-mediated transcription. J Virol (2010) 1.10
Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly. J Virol (2013) 1.09
The hepatitis C virus glycan shield and evasion of the humoral immune response. Viruses (2011) 1.07
The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res (2014) 1.07
A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission. PLoS One (2013) 1.04
Primary hepatocytes as targets for hepatitis C virus replication. J Viral Hepat (2008) 1.03
Neutralizing antibody response to hepatitis C virus. Viruses (2011) 1.03
Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents. PLoS Pathog (2014) 0.98
Hepatitis C virus egress and release depend on endosomal trafficking of core protein. J Virol (2010) 0.98
A new insight into hepatitis C vaccine development. J Biomed Biotechnol (2010) 0.94
Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses (2011) 0.93
Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains. J Infect Dis (2011) 0.93
Targeting host factors: a novel rationale for the management of hepatitis C virus. World J Gastroenterol (2009) 0.93
Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection. Viruses (2015) 0.91
Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses. J Virol (2014) 0.90
The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol (2014) 0.89
Disulfide bonds in hepatitis C virus glycoprotein E1 control the assembly and entry functions of E2 glycoprotein. J Virol (2012) 0.88
Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection? Curr Opin Immunol (2015) 0.88
Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles. J Virol (2011) 0.88
Recent advances in hepatitis C virus cell entry. Viruses (2010) 0.87
Immune control and failure in HCV infection--tipping the balance. J Leukoc Biol (2014) 0.87
Connections matter--how viruses use cell–cell adhesion components. J Cell Sci (2015) 0.87
Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol (2016) 0.86
Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus. J Virol (2016) 0.85
Determining the involvement and therapeutic implications of host cellular factors in hepatitis C virus cell-to-cell spread. J Virol (2014) 0.85
Cell-cell contact-mediated hepatitis C virus (HCV) transfer, productive infection, and replication and their requirement for HCV receptors. J Virol (2013) 0.85
Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases. BMC Med (2013) 0.84
Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses (2015) 0.84
Evasion of superinfection exclusion and elimination of primary viral RNA by an adapted strain of hepatitis C virus. J Virol (2013) 0.84
CD81 and hepatitis C virus (HCV) infection. Viruses (2014) 0.84
Characterization of Anti-HCV Antibodies in IL-10-Treated Patients. Viral Immunol (2010) 0.84
Novel function of CD81 in controlling hepatitis C virus replication. J Virol (2010) 0.84
CD81-receptor associations--impact for hepatitis C virus entry and antiviral therapies. Viruses (2014) 0.83
Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture. PLoS One (2012) 0.83
Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach. J Virol (2015) 0.83
Analysis of the evolution and structure of a complex intrahost viral population in chronic hepatitis C virus mapped by ultradeep pyrosequencing. J Virol (2014) 0.83
Apolipoprotein E, but Not Apolipoprotein B, Is Essential for Efficient Cell-to-Cell Transmission of Hepatitis C Virus. J Virol (2015) 0.82
Detecting host factors involved in virus infection by observing the clustering of infected cells in siRNA screening images. Bioinformatics (2010) 0.82
Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus. PLoS One (2013) 0.81
New Methods in Tissue Engineering: Improved Models for Viral Infection. Annu Rev Virol (2014) 0.81
Functional characterization of nuclear localization and export signals in hepatitis C virus proteins and their role in the membranous web. PLoS One (2014) 0.81
Human metapneumovirus Induces Reorganization of the Actin Cytoskeleton for Direct Cell-to-Cell Spread. PLoS Pathog (2016) 0.81
Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model. J Virol (2015) 0.80
New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A. J Virol (2015) 0.80
Lipoprotein Receptors Redundantly Participate in Entry of Hepatitis C Virus. PLoS Pathog (2016) 0.79
Tamiflu-resistant but HA-mediated cell-to-cell transmission through apical membranes of cell-associated influenza viruses. PLoS One (2011) 0.79
Differential effect of p7 inhibitors on hepatitis C virus cell-to-cell transmission. Antiviral Res (2013) 0.79
Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes. Cell Rep (2016) 0.78
Viral kinetics suggests a reconciliation of the disparate observations of the modulation of claudin-1 expression on cells exposed to hepatitis C virus. PLoS One (2012) 0.78
HCV animal models: a journey of more than 30 years. Viruses (2009) 0.78
Structural Studies of Chikungunya Virus-Like Particles Complexed with Human Antibodies: Neutralization and Cell-to-Cell Transmission. J Virol (2015) 0.78
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol (2002) 11.99
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol (2003) 3.84
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69
CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol (2004) 3.53
Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2006) 3.44
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10
Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol (2006) 2.77
Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol (2006) 2.65
Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology (2011) 2.51
Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med (2011) 2.47
Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol (2006) 2.45
Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology (2008) 2.43
Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS (2006) 2.23
Diverse CD81 proteins support hepatitis C virus infection. J Virol (2006) 2.07
Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2006) 2.05
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology (2006) 2.04
Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology (2010) 1.92
Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology (2010) 1.87
Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology (2008) 1.82
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer (2012) 1.76
Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol (2004) 1.76
Superinfection exclusion in cells infected with hepatitis C virus. J Virol (2007) 1.71
Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice. J Hepatol (2010) 1.70
Organellar dynamics during the cell cycle of Toxoplasma gondii. J Cell Sci (2008) 1.70
Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol (2007) 1.68
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2010) 1.67
Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem (2010) 1.67
Golgi biogenesis in Toxoplasma gondii. Nature (2002) 1.67
CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol (2008) 1.62
Inferring viral quasispecies spectra from 454 pyrosequencing reads. BMC Bioinformatics (2011) 1.62
Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology (2010) 1.58
Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology (2008) 1.55
Measuring tubulin content in Toxoplasma gondii: a comparison of laser-scanning confocal and wide-field fluorescence microscopy. Proc Natl Acad Sci U S A (2002) 1.55
Development of the antibody response in acute HIV-1 infection. AIDS (2004) 1.54
Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responses. J Hepatol (2004) 1.51
Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol (2008) 1.48
Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication. Hepatology (2013) 1.47
Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J Virol (2009) 1.44
Effect of cell polarization on hepatitis C virus entry. J Virol (2007) 1.41
Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol (2010) 1.37
HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe (2013) 1.37
IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology (2012) 1.36
Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology (2010) 1.35
Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis (2008) 1.30
A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology (2011) 1.28
Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine (2007) 1.28
The PI3K p110delta is required for down-regulation of RAG expression in immature B cells. J Immunol (2007) 1.27
A cluster of cases of human-to-human transmission caused by severe fever with thrombocytopenia syndrome bunyavirus. Int J Infect Dis (2012) 1.27
In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc Natl Acad Sci U S A (2008) 1.25
Renal clearance of gamma-hydroxybutyric acid in rats: increasing renal elimination as a detoxification strategy. J Pharmacol Exp Ther (2005) 1.24
Characterization of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins. J Virol (2004) 1.23
In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology (2011) 1.23
Hepatitis C virus entry: beyond receptors. Rev Med Virol (2012) 1.23
Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. Gastroenterology (2009) 1.17